SCHEDULE 13G/A: Poplar Point Capital Management Discloses 12.7% Passive Stake in NovaBay Pharmaceuticals
Beneficial Ownership Disclosure
Poplar Point Capital Management LLC and its affiliates have disclosed a 12.7% passive beneficial ownership stake in NovaBay Pharmaceuticals, Inc., as reported in an amended Schedule 13G filing.
Summary
- Poplar Point Capital Management LLC, Poplar Point Capital Partners LP, Poplar Point Capital GP LLC, and Jad Fakhry (collectively, the "Reporting Persons") have filed an amended Schedule 13G with the SEC.
- The filing indicates beneficial ownership of 620,685 shares of NovaBay Pharmaceuticals, Inc. Common Stock.
- This ownership represents approximately 12.7% of the outstanding Common Stock, calculated based on 4,885,693 shares outstanding as of November 4, 2024, as reported by the Issuer.
- The Reporting Persons hold shared voting power and shared dispositive power over all 620,685 shares.
- The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of NovaBay Pharmaceuticals, Inc., other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of passive ownership and does not contain performance or forward-looking statements.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by Poplar Point Capital Management in NovaBay Pharmaceuticals, which is a common practice in the investment management industry where funds acquire substantial stakes in publicly traded companies for investment purposes. It does not suggest any specific industry trend beyond typical portfolio management activities.
Stakeholder Impact
- This disclosure informs existing shareholders of a new significant passive investor, which could be viewed positively as a vote of confidence or neutrally as a standard institutional investment. The filing explicitly disclaims any intent to influence or change control of the issuer. There is no direct impact on employees, customers, suppliers, or creditors based on the information provided.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | Date as of which NovaBay Pharmaceuticals, Inc. reported 4,885,693 shares of Common Stock outstanding in its Quarterly Report on Form 10-Q. |
| 2025-01-31 | Date of event which requires the filing of this statement. |
| 2025-02-06 | Date of signing and filing of the Schedule 13G Amendment No. 1. |
Keywords
NovaBay Pharmaceuticals, Poplar Point Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Passive Investment, SEC Filing, NBY
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.